Joule Biotechnologies Elects Graham Allison to Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Joule Biotechnologies, Inc., an innovative bioengineering startup developing game-changing alternative energy solutions, today announced the election of Graham Allison to its board of directors.

Dr. Allison is the Douglas Dillon professor and Director of the Belfer Center for Science and International Affairs at Harvard University’s John F. Kennedy School of Government. As “founding dean” he built the leading school of public policy in the world. He served as Assistant Secretary of Defense in the first Clinton Administration and as Special Advisor to the Secretary of Defense under President Reagan. A recognized authority on US national security policy, he has served on the Defense Policy Board for Secretaries Weinberger, Carlucci, Cheney, Aspin, Perry and Cohen.

Dr. Allison’s background in the energy sector includes service as a director of the Getty Oil Company and Belco Oil and Gas, a member of the advisory boards of Hydro-Quebec and the International Energy Corporation, and Executive Director of the International Atomic Energy Agency’s Commission of Eminent Persons.

“I am pleased to join the board of a company that is inventing and delivering an entirely new category of clean, renewable fuel,” said Dr. Allison. “Joule’s proprietary technologies, engineering systems, business model, research and management team are compelling. I look forward to working with the other directors of the board as the company moves from the lab to industrial production over the next several years.”

“As Joule ramps up from successful laboratory scale to full production, we continually seek the strategic guidance of our world-class board of directors, whose considerable strengths range from business and entrepreneurship to life sciences and innovation,” said Bill Sims, President and CEO, Joule Biotechnologies. “We are very pleased to welcome Graham, whose proven leadership and knowledge of the energy sector will complement the board’s composition.”

In addition to Dr. Allison and Mr. Sims, Joule’s board comprises the following members:

Dr. Afeyan is Managing Partner and CEO of Flagship Ventures, a firm that manages over $600 million in early-stage funds across the sectors of Therapeutics, Life Science, and BioEnergy/Cleantech. A technologist, entrepreneur and venture capitalist, Dr. Afeyan has co-founded and helped build over 20 successful life science and technology start-ups during the past two decades. He was a member of the founding team, director and investor in successful ventures including Chemgenics Pharmaceuticals, Color Kinetics, Antigenics, EXACT Sciences and Adnexus Therapeutics. In addition to Joule, he is a director and co-founder of Affinnova, BG Medicine, Ensemble Discovery and Genstruct, among others.

Dr. Berry is a Partner at Flagship Ventures, where he focuses on investing in and founding early-stage life science and cleantech ventures. His work has led to 11 peer-reviewed publications, over 50 patents and applications, and over 25 awards and honors including the prestigious Lemelson-MIT Student Prize in 2005 for invention and innovation. He was named Innovator of the Year by Technology Review in its 2007 TR35 list of the world’s top 35 innovators under the age of 35.

Dr. Papadopoulos is co-founder and chairman of Exelixis, a development-stage biotech company focused on novel small molecule therapeutics for the treatment of cancer and other serious diseases. He retired as Vice Chairman of Cowen & Co. in August 2006, where he focused on the biotechnology and pharmaceutical sectors. He previously spent 13 years as an investment banker at PaineWebber, where he was most recently Chairman of PaineWebber Development Corp., a subsidiary focusing on biotechnology. He is a co-founder and board member of Anadys Pharmaceuticals and Cellzome, and also serves on the boards of BG Medicine, Regulus Therapeutics and Biogen Idec.

About Joule Biotechnologies

Joule Biotechnologies, Inc. is tackling the global energy crisis with a game-changing, renewable alternative to transportation fuels. Its patent-pending Helioculture™ technology surpasses the limitations of biomass-derived fuel approaches by using sunlight to convert CO2 directly into Joule™ liquid energy. This direct-to-fuel conversion requires no fresh water and minimal non-agricultural land, avoids costly intermediaries and processing, and finally enables the scale, unlimited quantities and pricing required for energy independence. Founded in 2007 by Flagship Ventures, Joule is privately held and headquartered in Cambridge, Massachusetts. Additional information is available at www.joulebio.com.

Contacts

Schwartz Communications
Dan Borgasano, 781-684-6660
joule@schwartz-pr.com